Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
2015 · Atherosclerosis · 186 citations
https://doi.org/10.1016/j.atherosclerosis.2015.11.010